The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

About Us

Why is genetic testing key following an AML diagnosis?

Jeffrey Lancet

January 6, 2021

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, Know AML spoke to Jeffrey Lancet, Moffitt Cancer Center, Tampa, US. We asked, Why is genetic testing key following an acute myeloid leukemia diagnosis? Lancet explains the reasons why genetic testing is so important at the time of acute myeloid leukemia diagnosis. He underlines three main reasons: prognostic purposes, choice of the initial therapy, and disease tracking.